Iwona D.
- Country
- Poland
- Department
- Oddział Onkologii Klinicznej
Research Overview
- A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
- A Phase III Randomized Double-Blind Study of Pembrolizumab, Trastuzumab, and Chemotherapy in HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Tailored Ibrutinib and Venetoclax Regimens in Untreated Chronic Lymphocytic Leukemia: A Multicohort Efficacy Evaluation
Data & Insights
Has run more than one trial at 357 of 626 partner sites.
Specializations
Hematologic Oncology
The investigator specializes in treating hematologic malignancies, with particular expertise in both chronic and acute leukemias.
- Chronic Lymphocytic Leukemia (CLL) treatment approaches
- Acute Myeloid Leukemia (AML) therapeutic strategies
- Novel combination therapies
Working with targeted therapies including BTK inhibitors and BCL-2 inhibitors for blood cancers.
Precision Medicine
Focuses on developing personalized treatment strategies based on molecular and genetic markers in blood cancers.
- Molecular-guided therapy selection
- Genetic mutation analysis in leukemia
- Biomarker-driven treatment approaches
Specializes in matching specific genetic profiles with targeted therapeutic interventions.
Innovative Therapeutics
Explores novel therapeutic combinations incorporating both established and investigational agents.
- Targeted therapy combinations
- Immunotherapy applications
- Chemoimmunotherapy optimization
Evaluates emerging treatment modalities against standard-of-care approaches in hematologic malignancies.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.